Skip to main content
Full access
Letters
Published Online: 1 April 2012

Citalopram and Nightmares

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Citalopram is a selective serotonin reuptake inhibitor(SSRI). It is very selective and potent inhibitor of serotonin (5-HT) reuptake and acts by binding directly to the serotonin transporter(5-HTT).1 It is one of the most commonly prescribed antidepressant in United States. Nightmares are a rare side effect of SSRIs. We report a first ever case, to our knowledge, of a patient who developed severe nightmares on initiating therapy with citalopram, which necessitated stopping of the drug.

Case Report

Mr. A is a 55 year old veteran with no past psychiatric history who came to our emergency room in March 2011, complaining of feeling depressed and suicidal. On evaluation he reported depressed mood, anhedonia, poor sleep, hopelessness, poor energy level and poor concentration. He also reported having thoughts that life is not worth living but denied any plan to end his life. His recent stressors include losing his job, family and being homeless. He was admitted to inpatient psychiatric unit and was started on citalopram 20 mg PO everyday for depression. He was also restarted on his home medications which included benazapril, nifedipine, omeprazole and warfarin. He tolerated citalopram well for first five days but on the sixth day, he reported having vivid scary dreams in which he sees himself committing suicide by jumping in front of a train. He described these dreams as memorable and intense. He denies having any history of nightmares in the past. He reported having similar nightmare in which he jumps in front of a train for next two days. He woke up from sleep every time frightened and anxious. He then requested to stop citalopram and be given another antidepressant. Citalopram was stopped and patient was started on wellbutrin. The nightmares disappeared a day after stopping citalopram.

Discussion

Nightmares occur only in REM sleep. Many studies show that most antidepressants including citalopram prolong REM sleep latency and suppress REM sleep time2 and are therefore expected to reduce or suppress nightmares. In our patient, the temporal relationship between the initiation of treatment with citalopram and onset of nightmares suggest a causal etiology. A serotonergic process therefore seems to be involved in dreaming in some patients. Stimulation of 5HT2 receptors may in some cases is associated with alterations in dreaming activity such as nightmares. This is evident in efficacy of 5HT2 antagonists such as cyproheptadine and mirtazipine in the treatment of nightmares especially in posttraumatic stress disorder. There have been case reports citing other antidepressants, Mirtazipine3 and Bupropion,4 causing nightmares. Both of them are known to increase REM sleep. There have also been reports citing venlafaxine and fluoxetine5 causing nightmares. Citalopram causing nightmares have never been reported before. Clinicians should be aware of this side effect as it can potentially affect treatment adherence.

References

1.
Owens MJ, Morgan WN, Plott SJ, et al.: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283:1305–1322
2.
Sharpley AL, Cowen PJ: Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 1995; 37:85–98
3.
Mathews M, Basil B, Evcimen H, et al.: Mirtazapine-induced nightmares. Prim Care Companion J Clin Psychiatry 2006; 8:311
4.
Balon R: Bupropion and nightmares. Am J Psychiatry 1996; 153:579–580
5.
Lepkifker E, Dannon PN, Iancu I, et al.: Nightmares related to fluoxetine treatment. Clin Neuropharmacol 1995; 18:90–94

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E43
PubMed: 22772700

History

Published online: 1 April 2012
Published in print: Spring 2012

Authors

Affiliations

Gurvinder Arora, M.D
Department of Psychiatry Veterans Affairs Hospital, East Orange, New Jersey
Gurpreet Sandhu, M.D
Department of Psychiatry Veterans Affairs Hospital, East Orange, New Jersey
Cecilia Fleser, M.D
Department of Psychiatry Veterans Affairs Hospital, East Orange, New Jersey

Notes

Corresponding author’s Telephone no- 3478706054 e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share